Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/164429
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZinger, Nicoleen_US
dc.contributor.authorPonath, Geralden_US
dc.contributor.authorSweeney, Elizabethen_US
dc.contributor.authorNguyen, Thanh D.en_US
dc.contributor.authorLo, Chih Hungen_US
dc.contributor.authorDiaz, Ivanen_US
dc.contributor.authorDimov, Alexeyen_US
dc.contributor.authorTeng, Leileien_US
dc.contributor.authorZexter, Lilyen_US
dc.contributor.authorComunale, Josephen_US
dc.contributor.authorWang, Yien_US
dc.contributor.authorPitt, Daviden_US
dc.contributor.authorGauthier, Susan A.en_US
dc.date.accessioned2023-01-25T01:21:55Z-
dc.date.available2023-01-25T01:21:55Z-
dc.date.issued2022-
dc.identifier.citationZinger, N., Ponath, G., Sweeney, E., Nguyen, T. D., Lo, C. H., Diaz, I., Dimov, A., Teng, L., Zexter, L., Comunale, J., Wang, Y., Pitt, D. & Gauthier, S. A. (2022). Dimethyl fumarate reduces inflammation in chronic active multiple sclerosis lesions. Neurology® Neuroimmunology & Neuroinflammation, 9(2), e1138-. https://dx.doi.org/10.1212/NXI.0000000000001138en_US
dc.identifier.issn2332-7812en_US
dc.identifier.urihttps://hdl.handle.net/10356/164429-
dc.description.abstractBACKGROUND AND OBJECTIVES: To determine the effects of dimethyl fumarate (DMF) and glatiramer acetate on iron content in chronic active lesions in patients with multiple sclerosis (MS) and in human microglia in vitro. METHODS: This was a retrospective observational study of 34 patients with relapsing-remitting MS and clinically isolated syndrome treated with DMF or glatiramer acetate. Patients had lesions with hyperintense rims on quantitative susceptibility mapping, were treated with DMF or glatiramer acetate (GA), and had a minimum of 2 on-treatment scans. Changes in susceptibility in rim lesions were compared among treatment groups in a linear mixed effects model. In a separate in vitro study, induced pluripotent stem cell-derived human microglia were treated with DMF or GA, and treatment-induced changes in iron content and activation state of microglia were compared. RESULTS: Rim lesions in patients treated with DMF had on average a 2.77-unit reduction in susceptibility per year over rim lesions in patients treated with GA (bootstrapped 95% CI -5.87 to -0.01), holding all other variables constant. Moreover, DMF but not GA reduced inflammatory activation and concomitantly iron content in human microglia in vitro. DISCUSSION: Together, our data indicate that DMF-induced reduction of susceptibility in MS lesions is associated with a decreased activation state in microglial cells. We have demonstrated that a specific disease modifying therapy, DMF, decreases glial activity in chronic active lesions. Susceptibility changes in rim lesions provide an in vivo biomarker for the effect of DMF on microglial activity. CLASSIFICATION OF EVIDENCE: This study provided Class III evidence that DMF is superior to GA in the presence of iron as a marker of inflammation as measured by MRI quantitative susceptibility mapping.en_US
dc.language.isoenen_US
dc.relation.ispartofNeurology® neuroimmunology & neuroinflammationen_US
dc.rights© 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.en_US
dc.subjectScience::Medicineen_US
dc.titleDimethyl fumarate reduces inflammation in chronic active multiple sclerosis lesionsen_US
dc.typeJournal Articleen
dc.contributor.schoolLee Kong Chian School of Medicine (LKCMedicine)en_US
dc.identifier.doi10.1212/NXI.0000000000001138-
dc.description.versionPublished versionen_US
dc.identifier.pmid35046083-
dc.identifier.scopus2-s2.0-85123664843-
dc.identifier.issue2en_US
dc.identifier.volume9en_US
dc.identifier.spagee1138en_US
dc.subject.keywordsDimethyl Fumarateen_US
dc.subject.keywordsMultiple Sclerosisen_US
dc.description.acknowledgementStudy Funding: This study was supported by NINDS/NIH RO1 NS102267, an investigator-initiated Clinical Trial/US-BGT-13-10516 (Biogen), BI-2007-36725 (NMSS), and by grant number UL1 TR 002384 from the National Center for Advancing Translational Sciences (NCATS) of the NIH. The Article Processing Charge was funded by the authors.en_US
item.fulltextWith Fulltext-
item.grantfulltextopen-
Appears in Collections:LKCMedicine Journal Articles
Files in This Item:
File Description SizeFormat 
e1138.full.pdf508.61 kBAdobe PDFThumbnail
View/Open

SCOPUSTM   
Citations 20

24
Updated on Jun 11, 2024

Web of ScienceTM
Citations 20

14
Updated on Oct 28, 2023

Page view(s)

92
Updated on Jun 18, 2024

Download(s)

28
Updated on Jun 18, 2024

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.